CN117004538B - Lactobacillus reuteri and application thereof - Google Patents
Lactobacillus reuteri and application thereof Download PDFInfo
- Publication number
- CN117004538B CN117004538B CN202311091740.6A CN202311091740A CN117004538B CN 117004538 B CN117004538 B CN 117004538B CN 202311091740 A CN202311091740 A CN 202311091740A CN 117004538 B CN117004538 B CN 117004538B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- helicobacter pylori
- reuteri
- lactobacillus
- probiotic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 64
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 64
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 38
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 33
- 206010019375 Helicobacter infections Diseases 0.000 claims abstract description 10
- 238000004321 preservation Methods 0.000 claims abstract description 10
- 239000006041 probiotic Substances 0.000 claims description 22
- 235000018291 probiotics Nutrition 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 230000000529 probiotic effect Effects 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000015140 cultured milk Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003833 bile salt Substances 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000009036 growth inhibition Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- 239000002609 medium Substances 0.000 description 15
- 239000000872 buffer Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 101150086731 ges-1 gene Proteins 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 3
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 3
- SCVOEYLBXCPATR-UHFFFAOYSA-L manganese(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O SCVOEYLBXCPATR-UHFFFAOYSA-L 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 101150114014 cagA gene Proteins 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 101150080234 vacA gene Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of microorganisms, and particularly discloses lactobacillus reuteri and application thereof. The preservation number of the lactobacillus reuteri (Limosifactobacillus reuteri) LR-T001 is CGMCC No.26792. The Lactobacillus reuteri LR-T001 provided by the invention has obvious growth inhibition effect on helicobacter pylori, can well grow in high-acid and high-bile salt concentration environments, can be well adapted to digestive tract environments, has good adhesion capability, can be rapidly planted in digestive tract systems to carry out rapid propagation, forms dominant bacterial colony, achieves the effect of rapidly and continuously inhibiting the growth of helicobacter pylori, effectively reduces the recurrence rate of helicobacter pylori infection, and has wide application prospects in the fields of clinical prevention, treatment and inhibition of helicobacter pylori infection related diseases and the like.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to lactobacillus reuteri and application thereof.
Background
Helicobacter pylori (Helicobacter pylori, HP) is a gram-negative bacillus that is S-shaped or curved. The cytotoxin-related gene (cagA) and the vacuolated toxin gene (vacA) are important pathogenic genes of helicobacter pylori, and are also main pathogenic factors causing chronic active gastritis, peptic ulcer, gastric MALT lymphoma and gastric cancer. Research shows that the incidence rate of atrophic gastritis and gastric cancer of the population with early age of primary infection of helicobacter pylori is relatively high, the helicobacter pylori infection and the death rate of gastric cancer are in parallel relation, and the world health organization already classifies the helicobacter pylori as a class I carcinogen. Thus, the control and treatment of helicobacter pylori is becoming more and more important.
At present, the conventional treatment of helicobacter pylori is mainly tetrad therapy (bismuth agent and proton pump inhibitor are combined with two antibiotics), and although the therapy can effectively eradicate helicobacter pylori in a short time, the helicobacter pylori is easy to be infected, even after healing, the helicobacter pylori can be infected again, the drug resistance of the helicobacter pylori continuously increases during the retreatment, and the eradication rate gradually decreases. Furthermore, the tetrad therapy causes the damage of normal flora of gastrointestinal tract and the colonization of external pathogenic bacteria, so that patients suffer from side effects of digestive tract such as abdominal pain, diarrhea, abdominal distention, constipation, nausea and the like. The research shows that some probiotics have the effect of resisting helicobacter pylori, and provide new thought for treating helicobacter pylori-caused diseases. However, the strains and the preparations thereof in the prior art have limited anti-helicobacter pylori effect, and still need to be matched with triple therapy or quadruple therapy to only play a role of auxiliary treatment. Although a small proportion of the probiotics may be used alone or in combination with other probiotics to treat helicobacter pylori, sufficient amounts are required to achieve a good therapeutic effect. Therefore, developing a method that can effectively inhibit helicobacter pylori infection is a problem to be solved.
Disclosure of Invention
Aiming at the problems of limited treatment effect, large dosage and the like of the existing probiotics for treating helicobacter pylori infection, the invention provides lactobacillus reuteri and application thereof.
In order to solve the technical problems, the technical scheme provided by the invention is as follows:
in a first aspect, the invention provides lactobacillus reuteri (Limosilactobacillus reuteri) LR-T001 with a preservation number of CGMCC No.26792.
Lactobacillus reuteri LR-T001 is selected from the feces of healthy human body, is classified and named as lactobacillus reuteri (Limosilactobacillus reuteri), and is preserved in China general microbiological culture collection center (CGMCC) for short in the year 03 and the month 10 of 2023, wherein the preservation number is CGMCC No.26792, and the preservation address is: the institute of microorganisms of national academy of sciences of China, no. 1, no. 3, north Chen West Lu, the Korean region of Beijing.
The biological characteristics of the lactobacillus reuteri LR-T001 provided by the invention are as follows: the MRS solid culture medium has the morphological characteristics of round, convex, milky, neat edge, poor transparency, small colony and short rod-shaped cell shape.
The Lactobacillus reuteri LR-T001 provided by the invention has obvious growth inhibition effect on helicobacter pylori, grows well in environments with high acid and high bile salt concentration, has high acid resistance and bile salt resistance, can be well adapted to the digestive tract environment, has good adhesion capability, can be rapidly planted in the digestive tract system to perform rapid propagation to form dominant bacterial colony, achieves the effect of rapidly and continuously inhibiting the growth of helicobacter pylori, effectively reduces the recurrence rate of helicobacter pylori infection, and has wide application prospects in the fields of clinical prevention, treatment and inhibition of helicobacter pylori infection related diseases, microbial treatment of gastric diseases and the like; in addition, the lactobacillus reuteri LR-T001 also has good hydrogen peroxide tolerance, and has wide application prospect in the food industry and extremely high practical value.
In a second aspect, the invention also provides a probiotic composition comprising said lactobacillus reuteri LR-T001.
Further, the probiotic composition further comprises at least one of bacillus amyloliquefaciens, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus plantarum or bifidobacterium.
Lactobacillus reuteri LR-T001 of the present invention may be used in combination with probiotics having anti-helicobacter pylori efficacy or probiotics regulating gastrointestinal function, which are common in the art.
In a third aspect, the invention also provides the use of lactobacillus reuteri LR-T001 or a probiotic composition in the manufacture of a medicament for the treatment of helicobacter pylori infection.
In a fourth aspect, the invention also provides an anti-helicobacter pylori pharmaceutical formulation comprising said lactobacillus reuteri LR-T001 or said probiotic composition, and a pharmaceutically acceptable carrier.
Further, the dosage form of the helicobacter pylori resistant pharmaceutical preparation is one of powder, granule, emulsion, capsule, tablet, pill or oral liquid.
Further, the pharmaceutical preparation comprises not less than 1×10 7 CFU/g L.reuteri LR-T001.
In a fifth aspect, the invention also provides application of the lactobacillus reuteri LR-T001 or the probiotic composition in preparing health-care food.
In a sixth aspect, the invention also provides a health food comprising the lactobacillus reuteri LR-T001 or the probiotic composition and a food additive.
Further, the health food is a probiotic solid beverage, fermented milk or fermented juice.
Further, the health food comprises not less than 1×10 6 CFU/mL of Lactobacillus reuteri LR-T001.
The lactobacillus reuteri LR-T001 can be prepared into a pharmaceutical preparation with common pharmaceutical auxiliary materials or carriers in the field, and can also be prepared into health-care food with prebiotics, plant extracts or other solid components which can be mixed with probiotics for eating, so that the lactobacillus reuteri LR-T001 is convenient for various people to use.
For example, lactobacillus reuteri LR-T001 lyophilized powder can be mixed with common food additives such as inulin, galactooligosaccharide, fructooligosaccharide, fruit powder or citric acid to obtain solid beverage fermented juice, or the fermented liquid of lactobacillus reuteri LR-T001 can be mixed with common food additives such as fruit juice, fructooligosaccharide, etc. to obtain fermented juice; can also be fermented with milk, sweetener, emulsifier, etc. to obtain fermented milk.
In a seventh aspect, the invention also provides a metabolite prepared by liquid fermentation of lactobacillus reuteri LR-T001 as described above.
Further, the preparation method of the metabolite comprises the following steps:
s1, inoculating lactobacillus reuteri LR-T001 seed liquid into a culture medium, and standing for cultivation to obtain lactobacillus reuteri LR-T001 fermentation liquid;
s2, centrifuging the lactobacillus reuteri LR-T001 fermentation liquid, and taking supernatant to obtain a metabolite of lactobacillus reuteri LR-T001.
The lactobacillus reuteri LR-T001 provided by the invention has high safety and strong stability, can effectively inhibit the growth of helicobacter pylori, solves the problems of gastrointestinal dysfunction, gastrointestinal dysbacteriosis, increased pathogenic bacteria drug resistance and the like caused by unreasonable use of antibiotics for a long time in the process of preventing and treating helicobacter pylori infection, can be used as functional probiotics for preparing foods, health care products or medicines, and has extremely high development prospect.
Drawings
FIG. 1 shows colony morphology of Lactobacillus reuteri LR-T001 according to the present invention;
FIG. 2 shows the cell morphology of Lactobacillus reuteri LR-T001 according to the invention under gram staining;
FIG. 3 is a phylogenetic tree of Lactobacillus reuteri LR-T001 constructed based on sequence similarity of the 16S rRNA genes in example 1.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The medium used in the examples:
skim milk medium: 10% of skim milk powder, 2% of glucose, 88% of distilled water and 7min of sterilization at 121 ℃ for standby.
MRS liquid medium: 1.0g of soybean peptone, 0.2g of sodium citrate, 2.0g of glucose, 0.2g of dipotassium hydrogen phosphate, 0.5g of anhydrous sodium acetate, 0.0054g of manganese sulfate pentahydrate, 0.5g of yeast powder, 0.02g of magnesium sulfate heptahydrate, 0.1g of tween-80, 1.0g of beef extract and 100mL of distilled water, wherein the pH is adjusted to 6.5, and the mixture is sterilized at 121 ℃ for 15min for later use.
MRS solid medium: 1.0g of soybean peptone, 0.2g of sodium citrate, 2.0g of glucose, 0.2g of dipotassium hydrogen phosphate, 0.5g of anhydrous sodium acetate, 0.0054g of manganese sulfate pentahydrate, 0.5g of yeast powder, 0.02g of magnesium sulfate heptahydrate, 0.1g of tween-80, 1.0g of beef extract, 1.5g of agar, 100mL of distilled water, and sterilizing for 15min at 121 ℃ for later use.
Fermentation medium: 10g of soybean peptone, 5g of anhydrous sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 2g of diammonium hydrogen citrate, 0.04g of manganese sulfate pentahydrate, 5g of yeast extract powder, 0.2g of magnesium sulfate heptahydrate, 1g of tween-80, 10g of beef extract powder, 1000mL of purified water and sterilizing at 121 ℃ for 15min.
Example 1
1. Strain screening
Adding 1g of human body healthy excrement into 9mL of sterile PBS buffer solution, shaking and fully mixing, sequentially carrying out 10-time gradient dilution, and respectively taking 100 mu L of 10 -3 ~10 -5 The gradient dilution is evenly coated on an MRS solid culture medium, the culture medium is placed in an anaerobic incubator for culturing for 48 hours at 37 ℃, opaque milky white, round, glossy, regular in edge, raised on the surface and wet colonies are selected, repeated streak purification culture is carried out on the MRS solid culture medium, and the individual morphology is observed through an optical microscope, so that the lactobacillus strain is obtained.
2. Morphological observation and physiological biochemical identification
Bacterial strain LR-T001 is inoculated on MRS solid culture medium, and is put into a constant temperature incubator at 37 ℃ for anaerobic culture for about 48 hours, and the colony morphology, colony edge, color, transparency and the like on the culture medium are observed.
Strain LR-T001 was round, convex, milky white, well-defined and poorly transparent on MRS solid medium, with smaller colonies and short bars in cell shape (as shown in fig. 1-2).
Molecular biological identification
The total DNA of strain LR-T001 is used as template, and the 16S rRNA universal primer 27F (5'-AG AGTTTGATCCTGGCTCAG-3') and 1492R (5'-TACGGCTACCTTGTTACGACTT-3') are used for PCR amplification, and the amplified product is identified by 1.2% agarose gel electrophoresis and then sent to the biological engineering (Shanghai) Co., ltd for determining the nucleic acid sequence.
The PCR amplification used a 20. Mu.L reaction system comprising: 2X Taq PCR Master Mix. Mu.L, 0.5. Mu.L each of the upstream and downstream primers (10. Mu.M), 1.0. Mu.L (20 ng/. Mu.L) of the DNA template and ddH 2 O 8.0μL。
PCR reaction conditions: firstly, pre-denaturing for 10min at 95 ℃; then denaturation at 95℃for 30s, annealing at 55℃for 30s, extension at 72℃for 30s, followed by 32 cycles in total and finally extension at 72℃for 10min.
The sequencing results of 16S rRNA were:
GGCTCAGGATGAACGCCGGCGGTGTGCCTAATACATGCAAGTCGTACGCACTGGCCCAACTGATTGATGGTGCTTGCACCTGATTGACGATGGATCACCAGTGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCCGGAGCGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAACAACAAAAGCCACATGGCTTTTGTTTGAAAGATGGCTTTGGCTATCACTCTGGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAATGGAACTGAGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGGCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGTTGGAGAAGAACGTGCGTGAGAGTAACTGTTCACGCAGTGACGGTATCCAACCAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTGCTTAGGTCTGATGTGAAAGCCTTCGGCTTAACCGAAGAAGTGCATCGGAAACCGGGCGACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGGAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATCTTGCGCTAACCTTAGAGATAAGGCGTTCCCTTCGGGGACGCAATGACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTACTAGTTGCCAGCATTAAGTTGGGCACTCTAGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGACGACGTCAGATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGTCGCAAGCTCGCGAGAGTAAGCTAATCTCTTAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTTGTAACGCCCAAAGTCGGTGGCCTAACCTTTATGGAGGG
comparing the 16S rRNA sequence of strain LR-T001 with the sequence in GenBank to obtain the 16S rRNA sequence of the similar lactobacillus reuteri standard strain, obtaining the evolutionary distance of the lactobacillus reuteri and related strains, and constructing a phylogenetic tree, as shown in figure 3. Based on the 16S rRNA sequence similarity analysis, strain LR-T001 was determined to be Lactobacillus reuteri (Limosilactobacillus reuteri).
The lactobacillus reuteri LR-T001 is preserved in China general microbiological culture Collection center (CGMCC) for a year of 2023 and a month of 03, and has a strain preservation number of CGMCC No.26792 and a preservation address of: the institute of microorganisms of national academy of sciences of China, no. 1, no. 3, north Chen West Lu, the Korean region of Beijing.
3. Activation and preservation of strains
First generation: the deposited strain was inoculated into 5ml of 10% skim milk medium, placed at 37℃for activation, and placed in a 4℃refrigerator for preservation until significant coagulation of skim milk in the medium was observed.
Second generation: the first-generation strain activated in advance is inoculated into 5mL MRS liquid culture medium according to the inoculation amount of 2%, and the strain is cultured for 12h at 37 ℃.
Third generation: the second-generation strain was inoculated into 5mL of MRS liquid medium at an inoculum size of 2%, and cultured at 37℃for 12 hours.
Fourth generation: the third generation strain was inoculated into 1mL of MRS liquid medium at an inoculum size of 5%, and cultured at 37℃for 12 hours.
The fourth generation strain is liquid strain for fermentation, a fermentation culture medium is adopted, the strain is inoculated according to 10% of the liquid in a fermentation tank, the pH value of a fermentation liquid is regulated to be constant 6.0 by 2mol/L sodium hydroxide solution during fermentation, the fermentation temperature is 37 ℃, the fermentation time is 7-8h, and the OD of the fermentation liquid is to be obtained 600 Stopping fermentation when the value is stable or no longer increases, reducing the temperature to 10-15 ℃, standing, centrifuging at 14000rpm for 1.5-2h, taking bacterial sludge, and adding the bacterial sludge according to the ratio of 1:0.32Adding a protective agent, wherein the protective agent comprises 12% of skim milk powder, 10% of trehalose, 0.5% of sodium glutamate, 1% of glycerol and the balance of sterile water, and after emulsification, putting into a vacuum freeze dryer for freeze drying, taking out, crushing, and detecting parameters such as viable count, physicochemical index and the like.
Example 2
Lactobacillus reuteri LR-T001 acid and bile salt resistance test:
lactobacillus reuteri LR-T001 fermentation broth in example 1 was centrifuged at 4000r/min at 4 ℃ for 3min, the supernatant was discarded, the cells were washed 2 times with PBS buffer, inoculated into modified MRS liquid media having pH values of 2.0, 2.5, 3.0, 3.5, 4.0, respectively, at 1% inoculum size, anaerobically cultured at 37 ℃, sampled at 0h, 2h, 4h, respectively, and viable count was performed. And cultured in a conventional MRS liquid medium as a control group. The results are shown in Table 1.
TABLE 1 viable count of bacterial powders of Lactobacillus reuteri LR-T001 at different pH values (10 11 CFU/g)
Time | pH2.0 | pH2.5 | pH3.0 | pH3.5 | pH4.0 | Control group |
0h | 3.8 | 4.9 | 3.9 | 4.2 | 4.2 | 4.0 |
2h | 3.1 | 3.3 | 3.5 | 3.2 | 3.5 | 3.8 |
4h | 2.6 | 3.7 | 3.1 | 2.8 | 3.9 | 3.6 |
Similarly, the strain was inoculated into an improved MRS liquid medium having a concentration of 0.1%, 0.3% and 0.6% by mass of bovine bile salt at an inoculum size of 1%, anaerobically cultured at 37℃and sampled at 0h, 2h, 4h and 6h, respectively, to count the number of viable bacteria. And cultured in a conventional MRS liquid medium as a control group. The results are shown in Table 2.
TABLE 2 viable count of bacterial powders of Lactobacillus reuteri LR-T001 at various pig bile salt concentrations (10) 11 CFU/g)
Time | 0.1% | 0.3% | 0.5% | Control group |
0h | 4.3 | 2.8 | 1.9 | 4.4 |
2h | 3.9 | 2.2 | 1.2 | 4.4 |
4h | 3.7 | 1.7 | 0.91 | 4.2 |
6h | 3.4 | 1.2 | 0.73 | 3.8 |
The results prove that the lactobacillus reuteri LR-T001 has higher acid resistance and bile salt resistance.
Example 3
Lactobacillus reuteri LR-T00 tolerates the ability to mimic the gut environment:
preparation of simulated gastric fluid:
accurately measuring 16.4mL of hydrochloric acid with the mass concentration of 100g/L, adding distilled water for dilution, adjusting the pH value to be 3.0, then adding pepsin, calculating the addition according to the mass concentration ratio of 1g/100mL, and filtering and sterilizing by using a microporous filter membrane after full dissolution to prepare simulated gastric juice for later use.
Preparation of artificial intestinal juice
Weighing KH 2 PO 4 3.4g, adding 250mL of distilled water for dissolution, adjusting the pH value to 6.8 by using 0.4g/100mL of NaOH solution, adding water for dilution to 500mL, then adding trypsin according to the mass concentration ratio of 1g/100mL, and filtering and sterilizing by using a microporous filter membrane after full dissolution to prepare simulated intestinal juice for later use.
The fermentation broth of Lactobacillus reuteri LR-T001 in example 1 was centrifuged at 8000r/min at 4℃for 4min, the supernatant was discarded, the cells were washed 2 times with PBS buffer, resuspended in a mixed solution of 1.9mL of simulated gastric fluid and 0.1mL of 10% skim milk solution, and after aerobic culture at 37℃for 2h, 100. Mu.L of the bacterial broth was taken for viable count.
Similarly, the fermentation broth of Lactobacillus reuteri LR-T001 in example 1 was centrifuged at 8000r/min at 4℃for 4min, the supernatant was discarded, the cells were washed with PBS buffer 2 times, resuspended in 1.9. Mu.L of simulated duodenal fluid, and after anaerobic culture at 37℃for 2h, 100. Mu.L of the cells were counted for viable bacteria. The results are shown in Table 3.
TABLE 3 resistance to simulated digestive tract environmental competence
The result shows that the lactobacillus reuteri LR-T001 has better capability of tolerating the simulated digestive tract and has higher application potential in the development of anti-helicobacter pylori medicines and health-care foods.
Lactobacillus reuteri LR-T001 tolerance to hydrogen peroxide:
the fermentation broth of Lactobacillus reuteri LR-T001 in example 1 was centrifuged at 4000r/min at 4℃for 3min, the supernatant was discarded, the cells were washed 2 times with PBS buffer, inoculated in a modified MRS liquid medium having hydrogen peroxide concentrations of 0.5mmol/L and 1.0mmol/L, respectively, at 1% inoculum size, and sampled at 0h, 3h, and 6h, respectively, for viable count. And a conventional MRS liquid medium was inoculated as a control group. The results are shown in Table 4.
TABLE 4 hydrogen peroxide resistance (10 11 CFU/mL)
Time | 0.5mmol/L | 1.0mmol/L | Control group |
0h | 3.6 | 1.7 | 4.3 |
3h | 3.1 | 1.3 | 4.2 |
6h | 2.6 | 0.6 | 4.0 |
Example 4
Adhesion capability test on human gastric mucosal cells GES-1:
regulating GES-1 cell concentration to 1×10 4 /mL,Added to a 96-well plate at 37℃with 5% CO 2 After the GES-1 cells are in an adherent state, washing the GES-1 cells for 3 times by using PBS buffer solution to obtain washed GES-1 cells (blank group).
Diluting helicobacter pylori suspension with sterile physiological saline to concentration of 2×10 7 CFU/mL, 1mL was added to the washed GES-1 cells at 37℃with 5% CO 2 After 2h incubation in the incubator (II), the unadsorbed H.pylori was washed 3 times with PBS buffer to clean the H.pylori infected GES-1 cells (HP group).
Into helicobacter pylori infected GES-1 cells, 10. Mu.L of Lactobacillus reuteri LR-T001 suspension (1.0X10. Mu.L of fermentation broth was centrifuged and resuspended in PBS) 8 CFU/mL), at 37℃with 5% CO 2 Is cultured for 2 hours to obtain the helicobacter pylori infected GES-1 cells (treatment group) treated with the Lactobacillus reuteri LR-T00.
After washing each well 5 times with PBS, 200. Mu.L of urease reagent was added to each cell group, and the mixture was washed with 5% CO at 37℃C 2 Culturing for 2 hours in an incubator of (2) to obtain culture solutions, and measuring the absorbance of the culture solutions of different groups at the wavelength of 550nm by using an enzyme-labeled instrument, wherein each group is subjected to 3 parallel experiments. The results are shown in Table 5.
Adhesion = (OD value of treatment group blank)/(OD value of HP group OD value of blank) ×100%
The adhesion of HP group is defined as 100%, the adhesion rate of treatment group is 21.2%, which shows that Lactobacillus reuteri LR-T001 can effectively reduce the colonization ability of helicobacter pylori to gastric mucosa cells, and is better used for eliminating helicobacter pylori after infection.
Example 5
Self-agglomerating ability detection
Centrifuging the lactobacillus reuteri LR-T001 fermentation broth of example 1 at 4000r/min and 4deg.C for 3min, discarding supernatant, washing thallus with PBS buffer for 2 times, and re-suspending in PBS buffer to obtain thallus concentration of 1×10 8 Bacterial suspension of CFU/mL is subjected to stationary culture at 37 ℃, supernatant liquid is taken at 0h, 2h, 4h, 6h, 12h and 24h,determination of OD 600 Values, 3 parallel experiments were set and self-coagulation rates were calculated. The results are shown in Table 5.
Self-aggregation ratio (%) = (a) 0 -A t )/A 0 ×100%
Wherein A0 is an OD of 0h 600 Value, at is OD At different sampling time points 600 Values.
TABLE 5 self-agglomeration rate
Hydrophobic ability detection
Centrifuging the lactobacillus reuteri LR-T001 fermentation broth of example 1 at 4000r/min and 4deg.C for 3min, discarding supernatant, washing thallus with PBS buffer for 2 times, re-suspending in PBS buffer, and adjusting bacterial suspension OD 600 Taking 2mL of the bacterial suspension and 2mL of dimethylbenzene in a test tube, vortex oscillating for 2min, standing at room temperature for 20min, vortex mixing, standing at room temperature for 20min for layering, and measuring absorbance value A at 600nm by water phase 1 3 replicates were measured in each group using PBS buffer as a blank.
Hydrophobicity= (1-A1/A0) ×100%
Wherein A0 is the initial absorbance value of the bacterial suspension at 600nm, and A1 is the absorbance value of the aqueous phase of the stationary phase layering.
The calculated hydrophobicity of lactobacillus reuteri LR-T001 was 89.5%.
The result proves that the lactobacillus reuteri LR-T001 has higher self-coagulation capability, can reach a plateau stage rapidly in 6 hours, is about 85.87 percent, has stronger hydrophobicity, can form a barrier rapidly on gastric mucosa, and prevents the colonization and infection of harmful bacteria.
Example 6
In vitro helicobacter pylori inhibition capability detection
Accurately measuring 16.4mL of hydrochloric acid with the mass concentration of 100g/L, adding distilled water for dilution, adjusting the pH value to 3.0, then adding pepsin, calculating the addition according to the mass concentration ratio of 1g/100mL, and filtering and sterilizing by using a microporous filter membrane after full dissolution to prepare simulated gastric fluid for later use.
Diluting helicobacter pylori suspension to a concentration of 1×10 8 CFU/mL, 2mL was added to 20mL simulated gastric fluid, and then 2mL of Lactobacillus reuteri LR-T001 suspension (fermentation broth was centrifuged and resuspended in PBS solution, 1.0X10) 7 CFU/mL) is placed on a micro-aerobic environment shaking table at 37 ℃ for culture, and the viable count is sampled and detected at 0h, 0.5h, 1h, 1.5h and 2h respectively, so as to calculate the inactivation rate. The blank was physiological saline at pH 7.0.
Inactivation ratio (%) = (number of viable bacteria detected at different times—number of initial viable bacteria)/number of initial viable bacteria×100%
The test result proves that the inactivation rate of the helicobacter pylori can reach more than 90% after 0.5h of culture, and the helicobacter pylori can be basically inactivated in 1.5h, so that the Lactobacillus reuteri LR-T001 can obviously inhibit the growth of the helicobacter pylori in the stomach environment.
In conclusion, the lactobacillus reuteri LR-T001 with the preservation number of CGMCC NO.26792 has strong self-condensation capability and high hydrophobicity, can quickly form a protective barrier on gastric mucosa, has high capability of adhering helicobacter pylori, can prevent the colonization of helicobacter pylori, effectively prevent and eliminate helicobacter pylori invaded in vivo, and has wide application prospect.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, or alternatives falling within the spirit and principles of the invention.
Claims (9)
1. Lactobacillus reuteri @ and its preparing processLimosilactobacillus reuteri) LR-T001, which is characterized in that the preservation number is CGMCC No.26792.
2. A probiotic composition comprising lactobacillus reuteri LR-T001 according to claim 1.
3. The probiotic composition of claim 2, further comprising at least one of bacillus amyloliquefaciens, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus plantarum, or bifidobacterium.
4. Use of lactobacillus reuteri LR-T001 according to claim 1 or a probiotic composition according to claim 2 for the manufacture of a medicament against helicobacter pylori infection.
5. An anti-helicobacter pylori pharmaceutical formulation comprising lactobacillus reuteri LR-T001 according to claim 1 or a probiotic composition according to claim 2, and a pharmaceutically acceptable carrier.
6. The helicobacter pylori resistant pharmaceutical preparation according to claim 5, wherein the dosage form is one of powder, granule, emulsion, capsule, tablet, pill or oral liquid.
7. Use of lactobacillus reuteri LR-T001 according to claim 1 or of a probiotic composition according to claim 2 in the preparation of a health food.
8. A health food comprising lactobacillus reuteri LR-T001 according to claim 1 or the probiotic composition according to claim 2, and a food additive.
9. The health food of claim 8, wherein the health food is a probiotic solid beverage, fermented milk or fermented juice.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311091740.6A CN117004538B (en) | 2023-08-28 | 2023-08-28 | Lactobacillus reuteri and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311091740.6A CN117004538B (en) | 2023-08-28 | 2023-08-28 | Lactobacillus reuteri and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117004538A CN117004538A (en) | 2023-11-07 |
CN117004538B true CN117004538B (en) | 2024-03-26 |
Family
ID=88561908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311091740.6A Active CN117004538B (en) | 2023-08-28 | 2023-08-28 | Lactobacillus reuteri and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117004538B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013027087A1 (en) * | 2011-08-23 | 2013-02-28 | Compagnie Gervais Danone | A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection |
CN113337431A (en) * | 2021-06-04 | 2021-09-03 | 青岛诺森生物技术有限责任公司 | Lactobacillus reuteri NSL0501 for inhibiting helicobacter pylori as well as biological agent and application thereof |
WO2023060074A1 (en) * | 2021-10-04 | 2023-04-13 | University Of Virginia Patent Foundation | A live cell assay to determine permeability of test molecules to and/or within the peptidoglycan scaffold of bacteria cells |
CN116004456A (en) * | 2022-12-27 | 2023-04-25 | 广西爱生生命科技有限公司 | Lactobacillus reuteri A21325 for inhibiting helicobacter pylori infection and application thereof |
CN116076736A (en) * | 2023-04-07 | 2023-05-09 | 北京东方红航天生物技术股份有限公司 | Anti-claustrophobic stomach nourishing composition and application thereof |
CN116590357A (en) * | 2023-06-08 | 2023-08-15 | 江西仁仁健康微生态科技有限公司 | Application of lactobacillus reuteri in production of gamma-aminobutyric acid and sleep-aiding products |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3040412A4 (en) * | 2013-08-23 | 2017-04-05 | Consejo Superior De Investigaciones Científicas (CSIC) | Probiotic strain of lactobacillus reuteri exhibiting anti-helicobacter activity, a probiotic or biotherapeutic product comprising said strain, and the use thereof |
-
2023
- 2023-08-28 CN CN202311091740.6A patent/CN117004538B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013027087A1 (en) * | 2011-08-23 | 2013-02-28 | Compagnie Gervais Danone | A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection |
CN113337431A (en) * | 2021-06-04 | 2021-09-03 | 青岛诺森生物技术有限责任公司 | Lactobacillus reuteri NSL0501 for inhibiting helicobacter pylori as well as biological agent and application thereof |
WO2023060074A1 (en) * | 2021-10-04 | 2023-04-13 | University Of Virginia Patent Foundation | A live cell assay to determine permeability of test molecules to and/or within the peptidoglycan scaffold of bacteria cells |
CN116004456A (en) * | 2022-12-27 | 2023-04-25 | 广西爱生生命科技有限公司 | Lactobacillus reuteri A21325 for inhibiting helicobacter pylori infection and application thereof |
CN116076736A (en) * | 2023-04-07 | 2023-05-09 | 北京东方红航天生物技术股份有限公司 | Anti-claustrophobic stomach nourishing composition and application thereof |
CN116590357A (en) * | 2023-06-08 | 2023-08-15 | 江西仁仁健康微生态科技有限公司 | Application of lactobacillus reuteri in production of gamma-aminobutyric acid and sleep-aiding products |
Non-Patent Citations (6)
Title |
---|
Characterization of adhesion, anti-adhesion, co-aggregation, and hydrophobicity of Helicobacter pylori and probiotic strains;Nucharee Juntarachot等;J Taibah Univ Med Sci.;第18卷(第5期);第1048–1054页 * |
Inhibitory activity of Limosilactobacillus reuteri isolated from camel milk against Helicobacter pylori effects in human gastric epithelial cells;Fatemeh Forooghi Nia等;Biotechnology and Applied Biochemistry;摘要 * |
Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection;Costantino Dargenio等;Medicina;第第57卷卷(第第7期期);摘要 * |
Survival of Limosilactobacillus reuteri UBLRu-87 during passage through the in vitro gut model system;J.J. Ahire等;LWT;第164卷;摘要 * |
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori infection in C57BL/6 mice;Zhao, YY 等;FOOD & FUNCTION;第第13卷卷(第第21期期);第11061-11069页 * |
发酵乳杆菌FBJSYZ21-1缓解幽门螺杆菌感染的临床功效评价;张华月等;食品与发酵工业;第1-10页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117004538A (en) | 2023-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109679882B (en) | Enterococcus faecium DT1-1 and application thereof | |
CN113337431B (en) | Lactobacillus reuteri NSL0501 for inhibiting helicobacter pylori as well as biological agent and application thereof | |
CN113913346B (en) | Lactobacillus paracasei JN-1 and application thereof | |
CN114350578B (en) | Lactobacillus plantarum LP1Z for producing lysozyme and efficiently antagonizing multidrug-resistant helicobacter pylori and application thereof | |
CN113122466B (en) | Enterococcus faecalis and application thereof | |
CN113832077A (en) | Lactobacillus rhamnosus and application thereof | |
CN116024130A (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
CN113549567B (en) | Lactobacillus rhamnosus NSL0401 with defecation promoting function and application thereof | |
CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
CN109022313B (en) | Lactobacillus plantarum | |
CN114958658B (en) | Lactobacillus rhamnosus A21149 for inhibiting helicobacter pylori and application thereof | |
CN114540243A (en) | Lactobacillus rhamnosus capable of preventing and/or treating helicobacter pylori infection and application thereof | |
CN114317334B (en) | Lactobacillus sake capable of co-aggregating with helicobacter pylori and application thereof | |
CN114774315A (en) | Application of lactobacillus rhamnosus strain LRa05 in preparing immunity enhancing and/or eczema relieving product | |
CN113088468B (en) | Lactobacillus casei Ma. GLRGJ1 and application thereof | |
CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
CN117004538B (en) | Lactobacillus reuteri and application thereof | |
CN116445356A (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
CN116445327A (en) | Hypolipidemic multielement probiotics and application thereof | |
CN115838650A (en) | Lactobacillus plantarum and application thereof | |
CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
CN117106628B (en) | Lactobacillus acidophilus LA15 with immunoregulation capability and application, product and method thereof | |
CN114574405B (en) | Lactobacillus plantarum WKA86, application thereof in preparation of halitosis preventing and treating product and halitosis preventing and treating product | |
CN114262671B (en) | Lactobacillus helveticus for preventing and treating cholestasis type liver diseases and application thereof | |
CN117402794B (en) | Lactobacillus gasseri and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |